Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Estrogen and movement disorders
Autore:
Kompoliti, K;
Indirizzi:
Rush Univ, Rush Presbyterian St Lukes Med Ctr, Dept Neurol Sci, Sect Movement Disorders, Chicago, IL 60612 USA Rush Univ Chicago IL USA 60612 Movement Disorders, Chicago, IL 60612 USA
Titolo Testata:
CLINICAL NEUROPHARMACOLOGY
fascicolo: 6, volume: 22, anno: 1999,
pagine: 318 - 326
SICI:
0362-5664(199911/12)22:6<318:EAMD>2.0.ZU;2-Y
Fonte:
ISI
Lingua:
ENG
Soggetto:
OBSESSIVE-COMPULSIVE DISORDER; MPTP-INDUCED NEUROTOXICITY; MENSTRUAL-RELATED FLUCTUATIONS; DOPAMINE RECEPTOR SENSITIVITY; NEUROMODULIN MESSENGER-RNA; PARKINSONS-DISEASE; TOURETTES-SYNDROME; TARDIVE-DYSKINESIA; STEROID-HORMONES; SEX-DIFFERENCES;
Keywords:
estrogen; movement disorders; dopaminergic effects; neuroprotection; menopause;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
117
Recensione:
Indirizzi per estratti:
Indirizzo: Kompoliti, K 1725 W Harrison St,Suite 1106, Chicago, IL 60612 USA 1725 W Harrison St,Suite 1106 Chicago IL USA 60612 60612 USA
Citazione:
K. Kompoliti, "Estrogen and movement disorders", CLIN NEUROP, 22(6), 1999, pp. 318-326

Abstract

Female sex hormones, and more specifically estrogen, can have biochemical and behavioral effects on the dopaminergic system. The effects of estrogen on the dopaminergic system can be classified as either neuroprotective or symptomatic. The neuroprotective effects refer to the ability of estrogen toprevent or modulate insults to the dopaminergic system and therefore to alter the natural history of disease processes affecting the dopaminergic circuitry in the brain. With regard to the symptomatic effects, support for suppressive and enhancing effects has been documented in humans and laboratory animals. The preclinical literature for neuroprotective and symptomatic effects of estrogen on the mesostriatal dopaminergic system forms the basis for studies on the influence of estrogen on the prevalence, disease progression, clinical signs, and medication effects of movement disorders, including Parkinson's disease, chorea, dystonia, ties, and myoclonus, Understanding the role of estrogen in modulating the dopaminergic system will allow clinicians to tailor therapies for women with movement disorders and optimize therapies for menstrually related symptom fluctuations. Such clarificationsmay also guide recommendations on the use of postmenopausal hormonal replacement therapy in women with movement disorders or those genetically at risk.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 15/07/20 alle ore 13:01:22